All check COVID-19 lgG/lgM Is a rapid immunochromatographic test for the qualitative detection of IgM and IgG Antibodies to the SARS-CoV-2 in human serum, plasma, venous or capillary whole blood. Results from the AllCheck COVID-19 IgG/IgM should not be used as the sole basis for diagnosis. 1. Rapid testing for SARS-CoV-2 antibodies within 10 minutes 2. Just 10L of specimen : serum, plasma or whole blood 3. Suitable for Point-of-Care testing 4. No need for extra equipment 5. Material provided : Device, Sample diluent 6. CE approved.
The outbreak of the novel coronavirus (COVID-19) rapidly transmit all over China and lots of countries. Although molecular test (RT-PCR) has become the standard method for diagnosis of this disease, the method has many limitations. In addition, the high false negative rates were reported. There is an urgent need for an accurate and rapid testing method that quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. GenBody COVID-19 IgM/IgG device is a chromatographic immunoassay kit for the rapid and differential detection of immunoglobulin M (lgM) and immunoglobulin G (IgG) against COVID-19 using serum, plasma and whole blood.
We hope you well and healthy. Here are the Medical Supplies we provide below: 1. COVID-19 TEST KIT(AG/lgG+lgM) 2. Hand Sanitizer 3. KF94 masks 4. 3ply Dental masks 5. Nitrile Gloves 6. Gowns 7. Sampling swab kits If you have any questions or if you interested in our product, please do not hesitate to contact us. Waiting for hearing from you. we wish you stay well and healthy. Thank you. Sincerely,
Helicobacter pylori is a parasitic bacterium in the stomach that lives between the gastric mucosa and mucus. According to the WHO, more than half of the world's population has H. pylori and is the third leading cause of cancer-related deaths. In 1994, the WHO's IARC classified H. Pylori as a Class 1 carcinogen. The incidence of H. pylori in developing countries is the highest worldwide, highlighting the need for highly accurate and manageable testing. By 2025, the H. pylori testing market is expected to be worth 6 billion. Accordingly, SML Genetree has developed a reagent that can diagnose Helico-bacter pylori and Clarithromycin-resistant mutants (A2142G, A2143G) through DNA extracted from human hygienic tissue using Real-time Polymerase Chain Reaction. Since it contains multiple gene regions, Helico-bacter pylori and Clarithromycin-resistant mutations can be detected sensitively, and high reproducibility has been demonstrated through repeated tests by serially diluting various positive samples and standards. In addition, as a result of clinical evaluation on human sanitary inspection tissue by commissioning a large domestic consignment inspection institution, high sensitivity and specificity were confirmed, proving its excellent clinical performance.
Ezplex�® SARS-CoV-2 G Kit, developed by SML Genetree, is a product that has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This is an in vitro diagnostic test that qualitatively detects the nucleic acids of SARS-CoV-2 (RdRp and N genes) in sputum to aid in emergency screening for COVID-19. This product can be used for a large amount of screening tests because it can perform a pooling test, unlike the products that the existing domestic companies have approved for emergency use by the FDA. For the combined test, samples are collected in units of 5 people and tested. If positive, individual tests are performed. In the case of a negative test, all tests are performed in a negative way. In particular, since a large number of samples are tested at once, the test is only possible with high sensitivity and specificity compared to existing diagnostic kits. According to the FDA, it was confirmed that 100% agreement was achieved in the result comparison test of individual and collective tests, and it was the 20th in the world and the first Korean company to pass the test. Excellent clinical performance was demonstrated by confirming high sensitivity and specificity through clinical evaluation, and stability was confirmed for 12 months through long-term storage tests. In January 2021, it was officially approved by the Korean Ministry of Food and Drug Safety (MFDS).
Ezplex MTBC/NTM Real-time PCR Kit is an in vitro diagnostic test that simultaneously detects Mycobacterium tuberculosis complex (MTBC) and 20 types of nontuberculous mycobacteria (NTM). Sensitivity : Multiple gene targets for MTBC and NTM. Clinical Performance: Validated clinical performance. Fast Results: Testing can be completed within 2 hours post extraction.
Description Foot-and-mouth disease virus (FMDV) causes an acute vesicular disease of cloven-hoofed animals and continues to be a threat to livestock worldwide with outbreaks causing severe economic losses. RIDX FMDV 3Diff/PAN Ag Combo Test Kit is a lateral flow chromatographic immunoassay for the qualitative detections of all 7 serotypes antigens of FMDV in bovine or porcine samples. 3Diff Ag Test: FMDV 3Diff detects FMDV Asia1, type A, and type O antigens. Three test lines (AS, A, O) and the control (C) line on the surface of the device. PAN Ag Test: FMDV PAN detects all 7 serotypes (type O, type A, type C, Asia1, SAT1, SAT2, and SAT3) of FMDV antigens. The test line (PAN) and the control (C) line on the surface of the device. If the FMDV antigens exist in the sample, that bind to the gold-conjugated FMDV antibodies. The complexes move through the membrane by capillary force and respond to the FMDV antibodies on the test line, resulting in a red line. The control line indicates that the test is performed correctly. The highly selective and sensitive four monoclonal antibodies to FMDV are used as capture and detector in RIDX�® FMDV 3Diff/PAN Ag Combo Test Kit. These antibodies are capable of detecting FMDV antigens in bovine and porcine samples with high accuracy. Specimen Bovine or porcine saliva, tissue or vesicular fluid around lip, tongue, gums, nose, or hoof Components FMDV 3Diff/PAN Ag combo test device (10 tests) Disposable swab (10 ea) Sample dilution buffer (1 vial) Disposable dropper (10 ea) Sample tube (10 ea) Features Clinical Sensitivity 1. Type O 88.2% (n=60/68) vs. PCR 2. Type A 100% (n=70), Asia1 100% (n=62), SAT1 100% (n=20), SAT2 100% (n=20), SAT3 100% (n=20), C 100% (n=20), in spiking samples with virus (titer: 1.0x105 TCID50/ml or higher) Clinical Specificity 1. Type O, type A and PAN: Bovine 100% (n=92), Swine 100% (n=400) 2. Type Asia1: Bovine 100% (n=92), Swine 99.5% (n=398/400) Differential diagnosis of 3 different serotypes (O, A, Asia1) of FMDV Concurrent diagnosis both of viral common antigens (all 7 serotypes) and serotype-specific antigens (O, A, Asia1) Packages 10 Tests/Kit 12 Kits/Box (120 Tests/Box) or 40 Kits/Box (400 Tests/Box)
FDA Approved Covid anti body test kit
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
1. PROTAN COVID-19 IgM/IgG Protan Covid-19 IgM/ IgG is In-Vitro kit for the qualitative measurement of anti-COVID-19 IgM and IgG antibodies in human whole blood, plasma, and serum which non-medical professionals can use. It produces results in 15 minutes without additional analyzer and is for easy, simple and rapid test just with finger tip blood. 2. PROTAN COVID-19 IgG Type2 In-Vitro kit for the qualitative measurement of SARS-Cov-2 IgG antibodies against SP-RBD in human whole blood, plasma, and serum. Protan Covid-19 IgG Type2 neutralizing Antibody Rapid Test Kit is to check whether the formation of Covid-19 Neutralizing antibodies After vaccination. Protan Covid-19 IgG Type2 is intended for the detection of neutralizing antibodies(IgG) against Covid-19 SP RBD(spike protein-receptor binding domain) in Human whole blood after vaccination.
MADE IN KOREA!! for more detail, Email US
It is a kit that can easily self-check Covid-19. It has an affordable price and high diagnostic accuracy. - Excellent accuracy and fast reading - Optimized for self-examination with easy and easy procedures - Two-color result display using Nano Band for easy reading - Use nasal swab samples
SARS-CoV-2 Test Kit made in Korea: - Target Gene: Orf-1ab gene & E-gene - Performance: Sensitivity: 77 genome copy equivalents/rxn - Running time:
PCL - Rapid Antigen Covid-19 test with saliva
